Chapter 438 - 262: International Hepatitis B-related Primary Liver Cancer Treatment Research Group (3)
Chapter 438: Chapter 262: International Hepatitis B-related Primary Liver Cancer Treatment Research Group (3)
This was a blatant scheme, but the representatives from the medical institutions present couldn’t resist the temptation!
A large number of medical institutions were prepared to be the first adopters, purchasing the Neutrino device at an astronomical price and importing the bundled antiviral drugs to conduct clinical trials in their own countries.
After all, this was the most advanced, cutting-edge technology in the world. With this brand-new treatment plan, these medical institutions could establish their industry status and reputation. Countless patients would flock to them, vying to become test subjects!
With endorsements from such renowned institutions and organizations as the International Anti-Cancer Association, Southern Country’s Ruihui Pharmaceutical, the University of Texas MD Anderson Cancer Center, and Berkeley University, and being the world’s leading revolutionary product, who could possibly refuse?
After stoking the interest and excitement of everyone at the conference, Edwards entered the operating room. The silver cloth was pulled away!
A massive collider-like device appeared before everyone. Its design was very similar to an MRI machine, but this one had a larger footprint, more complex operations, higher-end components, and consumed an enormous amount of electricity per startup.
This also meant the device itself would sell for an astronomical price. Furthermore, subsequent maintenance and repairs could only be performed by Edwards’ team, representing yet another bundled fee.
In addition, Edwards also planned to use the Neutrino therapy as a foundation to jointly establish an expert consensus and clinical practice standards for the diagnosis and treatment of HBV-related primary hepatocellular carcinoma.
The reason it hadn’t yet been elevated to the level of clinical guidelines was that the technology itself was still imperfect and immature. It required the joint effort of experts and scholars worldwide to advance it.
Edwards’ press conference was incredibly ambitious. As long as his grand plan was launched globally, selling the Neutrino device to major liver cancer treatment centers around the world, it would become the next gold standard for treating HBV-related primary hepatocellular carcinoma!
He, Edwards, would become the absolute authority in this field. And as for all the participants, as long as they accepted the contract, any future results from any team would become part of the expert consensus and clinical practice standards for the diagnosis and treatment of HBV-related primary hepatocellular carcinoma.
To that end, he was also preparing to establish an International HBV-Related Primary Hepatocellular Carcinoma Treatment Research Group!
Edwards would forever stand at the apex of the pyramid. As for subsequent contributors, he just needed to grant them some relevant status and nominal titles within this research group.
And this International HBV-Related Primary Hepatocellular Carcinoma Treatment Research Group of theirs would also control the initiative in negotiations with pharmaceutical companies, even deciding which drugs to place on the recommended medication list for treating HBV-related primary hepatocellular carcinoma!
As the chairman of the International Liver Cancer Association, Edwards was a master at orchestrating this kind of play.
Next, like the engine of a locomotive, the Neutrino machine began to start up. To generate the required neutrinos, it needed a process of preheating, acceleration, and selection, making the entire procedure quite long.
The patient selected for today was a young woman from the local state, a mid-stage patient with HBV-related primary hepatocellular carcinoma.
This was also her first time receiving treatment!
Amidst eager anticipation, the Neutrino machine completed its preliminary preparations. The patient, on a gurney, was slowly pushed into the treatment platform!
Due to the lack of an advanced, synchronized 3D imaging system, the audience could not see the specific operational process and could only wait nervously.
For most of the attendees, this was an unforgettable and incredible day, a milestone event in the history of treating HBV-related primary hepatocellular carcinoma.
But among the experts in attendance, for those who had collaborated with Wu Ting’s team or even personally participated in their surgeries, it was a different matter.
Professor Ma Mengchao, for example, inexplicably felt that it was all rather unimpressive.
’First of all, if this were Wu Ting’s team, they could have used a 3D imaging system for a synchronized display, showing each lesion area with precision...’
’Besides, no matter how you spin it, this is still just treatment for Stage II to Stage III patients (according to Wu Ting’s four-stage classification). Wu Ting’s team has already completed clinical data collection for their Stage II treatment; they just haven’t officially published it as a paper yet.’
’Furthermore, this project has inherent flaws with no clear solution. It requires combined antiviral therapy and supportive methods for liver protection. Isn’t that the very stuff Wu Ting’s research is exploring?’
’Fengmu Tiada has already entered clinical trials!’
’Of course, this project certainly has its groundbreaking aspects and highlights. Non-invasive treatment, the high-tech collider... it’s all very impressive, to be sure.’
After some careful consideration, Ma Mengchao still felt more inclined to support Wu Ting’s team.
It was just a shame that Wu Ting’s team lacked Edwards’ influence, appeal, and authority in the field of HBV-related primary hepatocellular carcinoma.
Ma Mengchao made a decision. After returning to his country, he would make a trip to Fan City to lend his support to the pilot project run by Wu Ting and the other four directors!
’Imagine, if Wu Ting’s team’s project really succeeded, it would be a direct check against what was now the world’s most advanced team—Edwards’ team!’
A rare fire ignited in Ma Mengchao’s heart.
Of course, most of the people there were completely captivated, shocked, and awestruck by Edwards’ Neutrino therapy!
As the Neutrino device operated, the first treatment was finally completed half an hour later!
To give the crowd a more immediate and direct impression, Edwards’ team had already treated other patients beforehand and had released their various metrics from before and after the treatment.
Clearly, the effects of the therapy itself were significant and stunning!
After the demonstration, Edwards returned from the operating room to the conference hall and gave a gentlemanly bow.
"Esteemed colleagues, patients, and friends, let us welcome the dawn of the Neutrino era!"
With Edwards’ perfect demonstration, the atmosphere in the hall reached a climax. A tsunami of cheers erupted, especially from the patients who had long suffered from liver cancer and their families. They cheered and cried out, tears of joy and excitement streaming from their eyes.
Professor Edwards had shown them hope for survival!
Once the emotional outburst in the conference hall had subsided, Edwards began to announce his grand plan:
"Next, we will proceed with signing cooperation agreements with major medical institutions, the screening and selection of new drugs from pharmaceutical companies, and the recruitment of the first batch of on-site volunteers!"
"All representatives of medical institutions interested in acquiring the Neutrino device, please proceed to our Area A2 to pick up an application form..."
"All pharmaceutical companies interested in the combined antiviral therapy, you are welcome to come to our Area A3 to pick up an application form..."
"All patients interested in becoming part of the first batch of volunteers, you are welcome to come to our Area A4 to pick up an application form..."
"The representatives from the first batch of selected medical institutions and pharmaceutical companies will have the opportunity to be considered for membership in our inaugural International HBV-Related Primary Hepatocellular Carcinoma Treatment Research Group!"
Edwards had brazenly laid out his ambitious plan!
Representatives from medical institutions and major pharmaceutical companies around the world, along with the long-suffering patients, all scrambled into their respective areas to grab application forms.
In the crowd, Han Shun, the director of Hepatic Tumor Surgery at Qinghe City’s 302 Hospital, joined the line in Area A2...
Li Tian and Yang Bao entered Area A3...
Many experts and patients from China entered the appropriate areas...
Pharmaceutical giants like Pfizer and Johnson & Johnson also entered the corresponding area...
Professor Ma Mengchao watched all of this calmly, as unmoving as a mountain.
...
...
「That night」 This international academic event in the field of HBV-related primary hepatocellular carcinoma shook the entire medical world.
Edwards, Neutrino, and the International HBV-Related Primary Hepatocellular Carcinoma Treatment Research Group became the focus of everyone’s attention.